FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington	D	C.	20549	

STATEMENT	OF	<b>CHANGES</b>	IN BEI	NEFICIAL	<b>OWNERSH</b>	IΙΡ
O 17 (1 E.W.E. 1 1	٠.	0.17 1.10 = 0		1L: :0:/ \L	O 1111E 1 1011	

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average but	rden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Sheridan William P				]	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [ BCRX ]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (speci				ner	
(Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200				1	3. Date of Earliest Transaction (Month/Day/Year) 12/15/2020							Senior VP - CMO					
(Street) DURHA (City)		C State)	27703 (Zip)		I. If Am	Line)						Form file	idual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
		Ta	able I - Non-	Derivat	ive S	ecurities	Acc	quired,	Dis	posed of	, or Ben	eficially	Owned				
Date				2A. Deemed Execution Date, if any (Month/Day/Year		Code V Amount (A) or D		d (A) or r. 3, 4 and 5) Price	5. Amount Securities Beneficial Owned Fo Reported Transactio	ly ( llowing ( on(s)	Form:	Direct II Indirect E tr. 4) C	. Nature of ndirect Beneficial Ownership Instr. 4)				
Table II - Derivat								uired, D	ispo	osed of,		ficially C	(Instr. 3 ar	nd 4)			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	4. Transa Code	action	5. Number of ion Derivative		Expiration Date (Month/Day/Year) of Section Underly Derivation		7. Title and of Securiti Underlying Derivative	. Title and Amount f Securities		9. Number derivative Securities Beneficial Owned Following Reported	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares		Transactio (Instr. 4)	on(s)		
Emp. Stock Option (Right to Buy)	\$8.31	12/15/2020		A		335,000 <sup>(1)</sup>		12/15/20	21	12/15/2030	Common Stock	335,000	\$0	335,000	0	D	

## Explanation of Responses:

1. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

/s/ Alane P. Barnes, by power of 12/17/2020 <u>attorney</u>

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.